论文部分内容阅读
目的:探讨透明帽辅助下食管静脉曲张硬化治疗的临床疗效与安全性.方法:78例肝硬化患者采用硬化剂治疗食管曲张静脉,分成内镜下直接注射治疗组(A组,n=47),透明帽辅助下注射治疗组(B组,n=31)治疗后1、6、12 mo行胃镜检查,比较食管曲张静脉治疗后改变、内镜治疗所需时间及术后不良反应发生率.结果:透明帽辅助组的食管曲张静脉治疗有效率高于直接注射治疗组(B组96.8%,A组74.5%,P<0.05),硬化剂使用量减少(A组80.54mL±18.72 mL,B组60.54 mL±12.74 mL P<0.05)及治疗次数减少(A组4.78次±1.24次B组2.78次±1.24次,P<0.05),内镜下治疗时间缩短(A组8.26 min±1.45 min,B组5.27 min±1.63 min,P<0.05),治疗周期缩短(A组29.31 d±6.29 d,B组20.20 d±4.79 d,P<0.05),并发症的发生率减少(A组48.9%,B组38.7%).结论:初步研究发现透明帽辅助下食管静脉曲张硬化治疗能降低术中出血风险、提高疗效.
Objective: To explore the clinical efficacy and safety of transparent cap-assisted esophageal variceal healing.Methods: 78 patients with cirrhosis treated with sclerotherapy for esophageal varices were divided into direct injection endoscopic treatment group (n = 47) (Group B, n = 31) underwent gastroscopy at 1, 6, and 12 months after treatment. The change of esophageal varices after treatment, the time required for endoscopic treatment, and the incidence of postoperative adverse reactions were compared. Results: The effective rate of esophageal variceal treatment in the cap-assisted group was higher than that of the direct injection therapy group (96.8% in group B, 74.5% in group A, P <0.05), and the amount of sclerosing agent used in group A was 80.54 mL ± 18.72 mL (A group, 4.78 times ± 1.24 times, B, 2.78 times ± 1.24 times, P <0.05), and the duration of endoscopic treatment was shorter (A group, 8.26 min ± 1.45 min, The duration of treatment was shorter in group B (5.27 min ± 1.63 min, P <0.05). The duration of treatment was shorter in group A (29.31 ± 6.29 days vs 20.20 days ± 4.79 days in group B, P <0.05) B group 38.7%) .Conclusion: The preliminary study found that the transparent cap-assisted esophageal variceal treatment can reduce the risk of intraoperative bleeding and improve the curative effect.